Comparative Pharmacology
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: POTASSIUM CHLORIDE 0 22 IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 3 IN DEXTROSE 5 IN PLASTIC CONTAINER.
POTASSIUM CHLORIDE 0.22% IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Potassium is the principal intracellular cation and is essential for maintaining cellular membrane potential, nerve impulse transmission, and muscle contraction. Dextrose provides calories and may prevent ketosis.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, muscle contraction, and cardiac function. Dextrose provides a source of calories and may enhance cellular potassium uptake via insulin-mediated shift.
Intravenous; typical adult dose is 10-20 mEq/hour, not exceeding 40 mEq/hour or 150 mEq/day, with continuous cardiac monitoring and serum potassium monitoring.
Intravenous infusion; typical adult dose: 10-20 mEq per hour, not exceeding 40 mEq per dose and 200 mEq per day, titrated based on serum potassium and ECG monitoring.
None Documented
None Documented
The elimination half-life of potassium is not applicable in the traditional sense because potassium is an endogenous ion under tight homeostatic control. After intravenous infusion of a potassium load, the plasma concentration declines with a distribution phase of about 1-2 hours, followed by a slower elimination phase reflecting cellular uptake and renal excretion, with a terminal half-life of approximately 6-8 hours in patients with normal renal function.
The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function. This reflects rapid redistribution and renal clearance. In anephric or oliguric patients, half-life is prolonged significantly, leading to accumulation and risk of hyperkalemia. Dextrose has a half-life of 15-20 minutes due to rapid cellular uptake and metabolism.
Renal: >90% of potassium intake is excreted by the kidneys, primarily via distal tubular secretion; fecal: <10%; minor sweat losses. In this formulation (KCl 0.22% in D5W), the potassium content is 2 mEq per 100 mL (approximately 20 mEq/L).
Renal excretion accounts for approximately 90% of potassium elimination, primarily via distal tubular secretion and reabsorption. Fecal excretion is minimal (<10%). The dextrose component is completely metabolized to CO2 and water, with no direct renal excretion.
Category C
Category C
Electrolyte Supplement
Electrolyte Supplement